ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Anti-CCP"

  • Abstract Number: 1298 • ACR Convergence 2024

    What Is an ANA and Why Should I Care? Strategies to Increase Understanding of Basic Rheumatologic Labs Within Medical Education

    Megan Schluentz1 and Sonam Kiwalkar2, 1Ochsner, New Orleans, LA, 2The Vancouver Clinic, Portland, OR

    Background/Purpose: A growing availability crisis in Rheumatology requires consideration of steps and best practices that might be employed to meet high demand. Besides increasing the…
  • Abstract Number: 1326 • ACR Convergence 2024

    Which Biomarkers Indicate Imminent Progression to Inflammatory Arthritis in High Risk CCP Positive Persons?

    Laurence Duquenne1, Didem Sahin Eroglu2, Jianhua Wu3, Kate Harnden1, Andrea Di Matteo4, Lucy Elizabeth Thornton5, Rahaymin Chowdhury5, Leticia Garcia-Montoya1, Kulveer Mankia6 and Paul Emery6, 11. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Leeds, United Kingdom, 21. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Ankara, Turkey, 31. University of Leeds, Leeds Institute for Data Analytics, Leeds, United Kingdom 2.Wolfson Institute of Population Health/Queen Mary University of London, UK, Leeds, 41. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Jesi, Italy, 51. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Leeds, 6University of Leeds, Leeds, United Kingdom

    Background/Purpose: A risk stratification model proposed a simple score using 4 biomarkers to identify those at high risk of developing inflammatory arthritis (IA) in primary…
  • Abstract Number: 1361 • ACR Convergence 2024

    The Effect of Disease Activity on Cardiovascular Risk Varies According to Rheumatoid Factor and Anticitrullinated Protein Antibody Status in Patients with Rheumatoid Arthritis

    George Karpouzas1, Virginia Pascual Ramos2, Elena Myasoedova3, Miguel Angel Gonzalez-Gay4, alfonso Corrales-Martínez5, Solbritt Rantapaa-Dahlqvist6, Petros Sfikakis7, Patrick Dessein8, Linda Tsang9, Carol Hitchon10, Hani El Gabalawy11, Piet Van RIel12, Irazu Contreras Yanez13, Iris Jazmín Colunga Pedraza14, Dionicio Galarza-Delgado15, jose Ramon Azpiri-Lopez16, Anne Grete Semb17, Durga P Misra18, Patrick Durez19, Brian Bridal Logstrup20, Ellen Margrethe Hauge21, George Kitas22 and Sarah Ormseth23, and ATACC-RA, 1Harbor-UCLA Medical Center, Torrance, CA, 2Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Federal District, Mexico, 3Mayo Clinic, Rochester, MN, 4University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, 5Hospital Universitario Marques de Valdecilla, Santander, Spain, 6Umeå University, Umeå, Sweden, 7Joint Academic Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens. Centre of New Biotechnologies and Precision Medicine (CNBPM), School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, 8University of Witwatersrand, Johannesburg, South Africa, 9University of Witwatersrand, Johanessburg, South Africa, 10University of Mannitoba, Winnipeg, Canada, 11University of Mannitoba, Winnipeg, MB, Canada, 12Radboud University Medical Center, Nijmegen, Netherlands, 13Instituto Nacional de las Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 14Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 15UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, 16Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 17Diakonhjemmet Hospital, Oslo, Norway, 18Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, 19UCLouvain, Louvain, Belgium, 20University of Aarhus, Aarhus, Denmark, 21Aarhus Universitetshospital, Aarhus, Denmark, 22The Dudley Group NHS Foundation Trust, Birmingham, United Kingdom, 23The Lundquist Institute, Torrance, CA

    Background/Purpose: Rheumatoid arthritis (RA) activity associates with cardiovascular (CV) risk. Anticitrullinated protein antibodies (ACPA) were linked to higher activity and lower remission rates. Treatment responses…
  • Abstract Number: 1388 • ACR Convergence 2024

    CXC Chemokine Ligand 13 and Rheumatoid Factor as Pharmacodynamic Biomarkers for Abatacept Treatment in Patients with Rheumatoid Arthritis

    Ting Wang1, Ryan Stultz1, Natalia Giltiay2, Christian Lood1 and Bobby Kwanghoon Han1, 1University of Washington, Seattle, WA, 2Division of Rheumatology, University of Washington, Seattle, USA, Seattle, WA

    Background/Purpose: Abatacept, a CTLA-4-Ig fusion protein, is widely used as a treatment for rheumatoid arthritis (RA). We conducted this study to identify novel predictive and…
  • Abstract Number: 2210 • ACR Convergence 2024

    Comparison of Dual RF and Anti-CCP Seropositive, Single Seropositive, and Seronegative RA on Radiographic Changes, Flares, and Mortality

    Rebecca Brooks1, Sara Achenbach2, Vanessa Kronzer1, Elena Myasoedova1, Cynthia Crowson1 and John Davis1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, Rochester, MN

    Background/Purpose: Both RF and anti-CCP are associated with erosive disease, increased disease activity, and adverse outcomes in RA. However, there have been limited studies investigating how…
  • Abstract Number: 2232 • ACR Convergence 2024

    Anti-RA33 Autoantibodies Are Unique, Sensitive Biomarkers for the Identification of Seronegative Rheumatoid Arthritis in a U.S. Cohort

    Andrew Concoff1, Touba Warsi2, Sepehr Taghavi2, Sudha Kumar2, Abigail Patalinghug2, Christine Schleif2, Brittany Partain3, Joseph Ahearn4, Nicole Wilson5, Susan Manzi5, Veena Joy6 and Tyler O'Malley7, 1Exagen, Inc., Los Angeles, CA, 2Exagen, Carlsbad, CA, 3Exagen, Boston, MA, 4Allegheny Health Network, Wexford, PA, 5Allegheny Health Network, Pittsburgh, PA, 6ThermoFisher, Philadelphia, PA, 7Exagen, Vista, CA

    Background/Purpose: Novel autoantibodies (Ab) capable of identifying unique subgroups of seronegative rheumatoid arthritis (SN-RA) while providing specificity for RA comparable to ACPA reflects an opportunity…
  • Abstract Number: 2238 • ACR Convergence 2024

    The Effect of Inflammation on Cardiovascular Risk in Rheumatoid Arthritis Varies According to Sex and Anticitrullinated Protein Antibody Status

    George Karpouzas1, Piet Van RIel2, Elena Myasoedova3, Miguel Angel Gonzalez-Gay4, alfonso Corrales-Martínez5, Solbritt Rantapaa-Dahlqvist6, Petros Sfikakis7, Patrick Dessein8, Linda Tsang9, Carol Hitchon10, Hani El Gabalawy11, Virginia Pascual Ramos12, Irazu Contreras Yanez13, Iris Jazmín Colunga Pedraza14, Dionicio Galarza-Delgado15, jose Ramon Azpiri-Lopez16, Anne Grete Semb17, Durga P Misra18, Patrick Durez19, Brian Bridal Logstrup20, Ellen Margrethe Hauge21, George Kitas22 and Sarah Ormseth23, and ATACC-RA, 1Harbor-UCLA Medical Center, Torrance, CA, 2Radboud University Medical Center, Nijmegen, Netherlands, 3Mayo Clinic, Rochester, MN, 4University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, 5Hospital Universitario Marques de Valdecilla, Santander, Spain, 6Umeå University, Umeå, Sweden, 7Joint Academic Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens. Centre of New Biotechnologies and Precision Medicine (CNBPM), School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, 8University of Witwatersrand, Johannesburg, South Africa, 9University of Witwatersrand, Johanessburg, South Africa, 10University of Mannitoba, Winnipeg, Canada, 11University of Mannitoba, Winnipeg, MB, Canada, 12Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Federal District, Mexico, 13Instituto Nacional de las Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 14Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 15UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, 16Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 17Diakonhjemmet Hospital, Oslo, Norway, 18Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, 19UCLouvain, Louvain, Belgium, 20University of Aarhus, Aarhus, Denmark, 21Aarhus Universitetshospital, Aarhus, Denmark, 22The Dudley Group NHS Foundation Trust, Birmingham, United Kingdom, 23The Lundquist Institute, Torrance, CA

    Background/Purpose: Disease activity associated with cardiovascular (CV) risk in rheumatoid arthritis (RA). Females with RA exhibit higher disease activity than males. Yet, males with RA…
  • Abstract Number: 2239 • ACR Convergence 2024

    Age, Seropositivity and Inflammation Determine Risk versus Benefit of Endogenous Estrogens on Coronary Atherosclerosis in Rheumatoid Arthritis

    George Karpouzas1, Bianca Papotti2, Sarah Ormseth3, Marcella Palumbo2, Elizabeth Hernandez3, Matthew Budoff4 and Nicoletta Ronda2, 1Harbor-UCLA Medical Center, Torrance, CA, 2University of Parma, Parma, Italy, 3The Lundquist Institute, Torrance, CA, 4Harbor-UCLA Medical Center and the Lundquist Institute for Biomedical Innovation, Torrance, CA

    Background/Purpose: Endogenous estrogens (E) appear cardioprotective in women in the general population. Yet, proinflammatory effects were described in chronic autoimmune diseases depending on stage, cell-type…
  • Abstract Number: 2240 • ACR Convergence 2024

    Methotrexate Use Influenced the Effect of Inflammation on Cardiovascular Risk Differently in Anticitrullinated Protein Antibody Negative and Positive Patients with Rheumatoid Arthritis

    George Karpouzas1, Piet Van RIel2, Elena Myasoedova3, Miguel Angel Gonzalez-Gay4, alfonso Corrales-Martínez5, Solbritt Rantapaa-Dahlqvist6, Petros Sfikakis7, Patrick Dessein8, Linda Tsang9, Carol Hitchon10, Hani El Gabalawy11, Virginia Pascual Ramos12, Irazu Contreras Yanez13, Iris Jazmín Colunga Pedraza14, Dionicio Galarza-Delgado15, jose Ramon Azpiri-Lopez16, Anne Grete Semb17, Patrick Durez18, Durga P Misra19, Brian Bridal Logstrup20, Ellen Margrethe Hauge21, George Kitas22 and Sarah Ormseth23, and ATACC-RA, 1Harbor-UCLA Medical Center, Torrance, CA, 2Radboud University Medical Center, Nijmegen, Netherlands, 3Mayo Clinic, Rochester, MN, 4University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, 5Hospital Universitario Marques de Valdecilla, Santander, Spain, 6Umeå University, Umeå, Sweden, 7Joint Academic Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens. Centre of New Biotechnologies and Precision Medicine (CNBPM), School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, 8University of Witwatersrand, Johannesburg, South Africa, 9University of Witwatersrand, Johanessburg, South Africa, 10University of Mannitoba, Winnipeg, Canada, 11University of Mannitoba, Winnipeg, MB, Canada, 12Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Federal District, Mexico, 13Instituto Nacional de las Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 14Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 15UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, 16Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 17Diakonhjemmet Hospital, Oslo, Norway, 18UCLouvain, Louvain, Belgium, 19Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, 20University of Aarhus, Aarhus, Denmark, 21Aarhus Universitetshospital, Aarhus, Denmark, 22The Dudley Group NHS Foundation Trust, Birmingham, United Kingdom, 23The Lundquist Institute, Torrance, CA

    Background/Purpose: Disease activity was linked to cardiovascular (CV) risk in rheumatoid arthritis (RA). Anticitrullinated protein antibody (ACPA) positivity associated with greater synovial inflammation, tumor necrosis…
  • Abstract Number: 0033 • ACR Convergence 2024

    Refined Autoantibody Profiles in RA Reveal That Primarily ACPAs Binding Non-glycine Citrulline Motifs Are Associated with Shared Epitope Alleles

    Linda Mathsson-Alm1, Helga Westerlind2, Isabel Gehring3, Monika Hansson2, Nasim Ghasemzadeh1, Jessica Rojas-Restrepo3, Saedis Saevarsdottir4, Joseph Sexton5, Siri Lillegraven6, Espen Haavardsholm6, Merete Hetland7, Hilde Hammer8, Tore K. Kvien9, Bente Glintborg10, Leonid Padyukov2, Johan Askling2 and Caroline Grönwall2, and the Danish Rheumatologic Biobank Study Group (the Biomarker Protocol), Swedish Rheumatology Quality Register Biobank Study Group (SRQb), 1Thermo Fisher Scientific, Uppsala, Sweden, 2Karolinska Institutet, Stockholm, Sweden, 3Thermo Fisher Scientific, Freiburg, Germany, 4University of Iceland, Reykjavik, Iceland, 5Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 6Diakonhjemmet Hospital, Oslo, Norway, 7Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, 8Diakonhjemmet Hospital, Oslo, Oslo, Norway, 9Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 10DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark

    Background/Purpose: Carriage of HLA-DRB1 shared epitope (SE) alleles and a history of smoking, have been identified as the most prominent risk factors for development of…
  • Abstract Number: 2250 • ACR Convergence 2024

    Cause Specific Mortality Differs in Rheumatoid Arthritis by Sex and Seropositivity

    Elena Joerns1, Ryan Lennon2, Cynthia Crowson2, Andrea Lopez-ruiz2, Roslin Jose George2, Vanessa Kronzer2, John Davis2 and Elena Myasoedova2, 1Mayo Clinic, Rochester, 2Mayo Clinic, Rochester, MN

    Background/Purpose: Persons with rheumatoid arthritis (RA) have an increased risk of mortality compared to the general population. Seropositivity has been shown to be associated with…
  • Abstract Number: 0035 • ACR Convergence 2024

    Anti-CCP Generation in the Female Genital Tract Is Increased During the Postpartum Period in Women Without RA

    Daniele Marcy1, Ashley Visser2, Claudia Lugo2, Kristin Sturm2 and Kristen Demoruelle3, 1University of Colorado Anschutz Medical Campus, Northglenn, CO, 2University of Colorado Anschutz Medical Campus, Aurora, CO, 3University of Colorado Anschutz Medical Campus, Golden, CO

    Background/Purpose: It is well established that women develop RA approximately three times more often than men. In addition, several risk factors for RA uniquely effect…
  • Abstract Number: 0392 • ACR Convergence 2023

    Novel Diagnostic Markers for Rheumatoid Arthritis Including Anti-CarP (Carbamylated Protein), Anti-Sa (Citrullinated Vimentin) and Anti-CEP1 (Citrullinated Enolase Peptide1) Are Frequently Positive in Diagnostic Profiles

    Jane Yang1, Rubio Punzalan1, Lehrhoff Andrew1, Michael Nappi1, Vincent ricchiuti2, Michael Zikry1 and Kelly Chun1, 1Labcorp, Calabasas, CA, 2Labcorp, Dublin, OH

    Background/Purpose: Despite the diagnostic contribution of Anti-CCP3.1 (cyclic citrillunated peptide) antibody and RF (rheumatoid factor) as classified by the 2010 ACR/EULAR RA criteria, approximately one-third…
  • Abstract Number: 0835 • ACR Convergence 2023

    Abatacept in Individuals at Risk of Developing Rheumatoid Arthritis: Results from the Arthritis Prevention in the Pre-clinical Phase of RA with Abatacept (APIPPRA) Trial

    Andrew Cope1, Marianna Jasenecova2, Joana Vasconcelos3, Andrew Filer4, Karim Raza5, Sumera Qureshi2, Maria Antonietta D'Agostino6, Iain McInnes7, John Isaacs8, Arthur Pratt9, Benjamin A Fisher4, Christopher Buckley10, Paul Emery11, Pauline Ho12, Maya Buch13, Coziana Ciurtin14, René Toes15, Thomas Huizinga15, Dirkjan van Schaardenburg16, Caroline Caroline17 and Toby Prevost3, 1King's College London, London, United Kingdom, 2Centre for Rheumatic Diseases, King's College London, London, United Kingdom, 3Nightingale-Saunders Clinical Trials & Epidemiology Unit, King's College London, London, United Kingdom, 4University of Birmingham, Birmingham, United Kingdom, 5Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, 6Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy, 7University of Glasgow, Glasgow, United Kingdom, 8Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom, 9Translational & Clinical Research Institute, University of Newcastle, Newcastle, United Kingdom, 10University of Oxford, Oxford, United Kingdom, 11Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 12Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, 13University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, 14Centre for Rheumatology Research, University College London, London, United Kingdom, 15Leiden University Medical Center, Leiden, Netherlands, 16Reade, Amsterdam, Netherlands, 17King's Clinical Trials Unit, King's College London, London, United Kingdom

    Background/Purpose: The definition of higher risk states for rheumatoid arthritis (RA) has been refined in more recent years through inclusion of serum autoantibodies and symptom…
  • Abstract Number: 0980 • ACR Convergence 2023

    Temporal Trends in Incidence Rates of Seropositive and Seronegative Rheumatoid Arthritis: A Danish Nationwide Population-based Study

    Bolette Soussi1, René Cordtz2, Kirsten Duch2, Salome Kristensen3, Asta Linauskas4, Christian Bork5, Erik Schmidt6 and Lene Dreyer3, 1Center of Rheumatic Research Aalborg, Department of Rheumatology, and Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark, 2Center of Rheumatic Research Aalborg, Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, 3Center of Rheumatic Research Aalborg, Department of Rheumatology, Aalborg University Hospital, and Department of Clinical Medicine, Aalborg University, Aalborg, Denmark, 4Department of Rheumatology, North Denmark Region Hospital, and Department of Clinical Medicine, Aalborg University, Hjørring, Denmark, 5Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark, 6Department of Medicine and Cardiology, Viborg Regional Hospital, and Department of Clinical Medicine, Aalborg University, Viborg, Aalborg, Denmark

    Background/Purpose: With growing availability of autoantibody testing and autoantibodies gaining more weight in the 2010 ACR/EULAR classification criteria of rheumatoid arthritis (RA), an increasing incidence…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology